Skip to main content
. 2019 Apr 12;30(5):523–532. doi: 10.1097/CAD.0000000000000772

Table 5.

Change from baseline in corrected QT interval versus talazoparib plasma concentration (PK/PD analysis population)

graphic file with name cad-30-523-g006.jpg